平肝潜阳法治疗高血压肝阳上亢证大鼠下丘脑、肾上腺的蛋白质组学研究
|
摘要
目的
1.建立正常大鼠、高血压肝阳上亢证大鼠及高血压肝阳上亢证平肝潜阳法治疗后大鼠的下丘脑和肾上腺组织双向凝胶电泳图谱。
2.观察高血压肝阳上亢证大鼠平肝潜阳法治疗前后下丘脑及肾上腺的蛋白质表达差异,从蛋白质组学水平探讨其降血压和改善肝阳上亢证症状的分子机制,为寻找新的药物标志蛋白提供理论依据。
方法
1.以SHR大鼠加灌服附子汤法制备高血压肝阳上亢证大鼠模型。
2.二维凝胶电泳分离大鼠下丘脑及肾上腺蛋白质,凝胶经考染显色后,PDQuest图像分析软件进行比较分析,获得差异表达蛋白质。
3.利用基质辅助激光解吸电离飞行时间质谱和数据库分析鉴定差异表达蛋白质。
结果
1.动物模型的复制:模型组和PGQYF组大鼠在附子汤灌胃3周后,其易激惹程度发生变化,多表现为Ⅲ级,且大部分出现了结合膜充血;饮水量明显增加;收缩压明显升高。与正常对照组及造模前比较,差异均具有统计学意义(P＜0.01)。经PGQYF治疗后(第6周末),其易激惹程度及结合膜充血均好转,易激惹程度多表现为Ⅰ和Ⅱ级,饮水量及收缩压较治疗前及模型组明显减少,差异均具有统计学意义(P＜0.01)。
2.各组总蛋白2-DE图谱的建立及差异蛋白质识别:建立了正常大鼠、高血压肝阳上亢证大鼠及平肝潜阳法治疗后大鼠重复性好的下丘脑和肾上腺组织蛋白质组表达图谱。通过PDQuest图像分析,发现了27个差异表达蛋白质点:和正常组比较,肝阳上亢模型组下丘脑图谱中1、2、4、5、7、8号蛋白质点、肾上腺图谱中2、3、5、6、7号蛋白质点表达上升2倍及以上,且其在PGQYF组中表达下降2倍及以上,大致处于与正常组同一水平或低于正常对照组低;肝阳上亢模型组下丘脑图谱中3、6、9、10、11、12、13、14、15号蛋白质点、肾上腺图谱中1、4、8、9、10、11、12号蛋白质点表达下降2倍及以上,且同一点在PGQYF组中表达上升2倍及以上,大致处于与正常组同一水平或高于正常对照组。
3.差异蛋白质点质谱鉴定及蛋白功能分类:选取25个蛋白质点进行质谱鉴定,成功鉴定22个蛋白质点。根据NCBI、MSDB数据库中提供的信息,这些差异蛋白质涉及多种蛋白种类,如参与能量代谢的酶类、抗氧化蛋白、神经内分泌相关蛋白、细胞信号转导蛋白、细胞骨架相关蛋白等。其中硫氧还蛋白过氧化物酶-Ⅱ(PRX-Ⅱ)、热休克蛋白-27(HSP-27)、膜联蛋白-Al(Annexin-Al)等蛋白可能与高血压肝阳上亢证及平肝潜阳治疗法密切相关。
结论
平肝潜阳法治疗后,高血压肝阳上亢证大鼠症状改善,血压降低,可能与下丘脑和肾上腺组织中某些蛋白质的改变有关。成功鉴定了高血压肝阳上亢证平肝潜阳法治疗前后下丘脑及肾上腺组织差异表达蛋白,为深入研究高血压病肝阳上亢证病理生理机制及平肝潜阳法治疗的作用分子机制奠定基础。
SUBJECT
1. To establish two-dimensional electrophoresis profiles with high resolution and reproducibility from hypothalamuses and adrenal glands of normal rats、hyperensive rats with hyperactivity of liver-yang and the hypertensive rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment.
2. To explore the different expression in hypothalamic and adrener-gdrenic proteins of hypertensive rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment, and probe into the hypertension pathogenesy and mechanism of decreasing the blood pressure and ameliorating the symptoms of Pinggan-Qianyang treatment from the level of proteomics, and provide theories evidences for new medical marked protein.
METHODS
1. Hypertensive rats with excessive rising of liver-yang model rats were prepared by spontaneous hypertensive rats (SHR) with drenching Aconiti Praeparatae Decoction.
2. Hypothalamic and adrenergdrenic proteins was separated by 2D gel electrophoresis (2-DE). After Coomasie briliant blue G250 staining, gel-image analysis was performed by using PDQuest, we get the differential expressed proteins.
3. The differential expressed proteins was identified by matrix_associated laser desorption/ionization time of flight massspectrometry (MALDI-TOF-MS) and database analysis.
RESULTS
1. The model of hyperensive rats with hyperactivity of liver-yangwere reproduced succeedly, and the curative effect of Pinggan-Qianyang treatment was good.
2. The 2-DE Patterns of hypothalamuses and adrenal glands of normal rats、SHR with hyperactivity of liver-yang and the rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment were presented.Gel-image analysis reveals that there are 27 differential protein spots.
3. The 22 of total 25 differential protein spots are successfully identified by MALDI-TOF-MS.The functions of these Proteins involve in metabolism, energy generation, transportation, antioxidation, sigal transduction and cytoskeleton etc according to information provided in NCBI and MSDB database. Among them, there are some proteins closely related to hypertension with hyperactivity of liver-yang and the Pinggan-Qianyang treatment, such as Peroxirdoxin-II、Heat shockprotein-27、Annexin-A1.
CONCLUSION
The blood pressure of hyperensive rats with hyperactivity ofliver-yang is reduced with symptoms ameliorated after taking Pinggan-Qianyang treatment, which might be related to the changes of hypothalamic and adrenergdrenic protein. Appreciated hypothalamic and adrenergdrenic differential expressed proteins with Pinggan-Qianyang treatment succeedly. This approachmay lay a foundation for the further investigation of pathogenic mechanisms in hypertension with hyperactivity of liver-yang and curative effect mechanisms of Pinggan-Qianyang treatment.
1.建立正常大鼠、高血压肝阳上亢证大鼠及高血压肝阳上亢证平肝潜阳法治疗后大鼠的下丘脑和肾上腺组织双向凝胶电泳图谱。
2.观察高血压肝阳上亢证大鼠平肝潜阳法治疗前后下丘脑及肾上腺的蛋白质表达差异,从蛋白质组学水平探讨其降血压和改善肝阳上亢证症状的分子机制,为寻找新的药物标志蛋白提供理论依据。
方法
1.以SHR大鼠加灌服附子汤法制备高血压肝阳上亢证大鼠模型。
2.二维凝胶电泳分离大鼠下丘脑及肾上腺蛋白质,凝胶经考染显色后,PDQuest图像分析软件进行比较分析,获得差异表达蛋白质。
3.利用基质辅助激光解吸电离飞行时间质谱和数据库分析鉴定差异表达蛋白质。
结果
1.动物模型的复制:模型组和PGQYF组大鼠在附子汤灌胃3周后,其易激惹程度发生变化,多表现为Ⅲ级,且大部分出现了结合膜充血;饮水量明显增加;收缩压明显升高。与正常对照组及造模前比较,差异均具有统计学意义(P＜0.01)。经PGQYF治疗后(第6周末),其易激惹程度及结合膜充血均好转,易激惹程度多表现为Ⅰ和Ⅱ级,饮水量及收缩压较治疗前及模型组明显减少,差异均具有统计学意义(P＜0.01)。
2.各组总蛋白2-DE图谱的建立及差异蛋白质识别:建立了正常大鼠、高血压肝阳上亢证大鼠及平肝潜阳法治疗后大鼠重复性好的下丘脑和肾上腺组织蛋白质组表达图谱。通过PDQuest图像分析,发现了27个差异表达蛋白质点:和正常组比较,肝阳上亢模型组下丘脑图谱中1、2、4、5、7、8号蛋白质点、肾上腺图谱中2、3、5、6、7号蛋白质点表达上升2倍及以上,且其在PGQYF组中表达下降2倍及以上,大致处于与正常组同一水平或低于正常对照组低;肝阳上亢模型组下丘脑图谱中3、6、9、10、11、12、13、14、15号蛋白质点、肾上腺图谱中1、4、8、9、10、11、12号蛋白质点表达下降2倍及以上,且同一点在PGQYF组中表达上升2倍及以上,大致处于与正常组同一水平或高于正常对照组。
3.差异蛋白质点质谱鉴定及蛋白功能分类:选取25个蛋白质点进行质谱鉴定,成功鉴定22个蛋白质点。根据NCBI、MSDB数据库中提供的信息,这些差异蛋白质涉及多种蛋白种类,如参与能量代谢的酶类、抗氧化蛋白、神经内分泌相关蛋白、细胞信号转导蛋白、细胞骨架相关蛋白等。其中硫氧还蛋白过氧化物酶-Ⅱ(PRX-Ⅱ)、热休克蛋白-27(HSP-27)、膜联蛋白-Al(Annexin-Al)等蛋白可能与高血压肝阳上亢证及平肝潜阳治疗法密切相关。
结论
平肝潜阳法治疗后,高血压肝阳上亢证大鼠症状改善,血压降低,可能与下丘脑和肾上腺组织中某些蛋白质的改变有关。成功鉴定了高血压肝阳上亢证平肝潜阳法治疗前后下丘脑及肾上腺组织差异表达蛋白,为深入研究高血压病肝阳上亢证病理生理机制及平肝潜阳法治疗的作用分子机制奠定基础。
SUBJECT
1. To establish two-dimensional electrophoresis profiles with high resolution and reproducibility from hypothalamuses and adrenal glands of normal rats、hyperensive rats with hyperactivity of liver-yang and the hypertensive rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment.
2. To explore the different expression in hypothalamic and adrener-gdrenic proteins of hypertensive rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment, and probe into the hypertension pathogenesy and mechanism of decreasing the blood pressure and ameliorating the symptoms of Pinggan-Qianyang treatment from the level of proteomics, and provide theories evidences for new medical marked protein.
METHODS
1. Hypertensive rats with excessive rising of liver-yang model rats were prepared by spontaneous hypertensive rats (SHR) with drenching Aconiti Praeparatae Decoction.
2. Hypothalamic and adrenergdrenic proteins was separated by 2D gel electrophoresis (2-DE). After Coomasie briliant blue G250 staining, gel-image analysis was performed by using PDQuest, we get the differential expressed proteins.
3. The differential expressed proteins was identified by matrix_associated laser desorption/ionization time of flight massspectrometry (MALDI-TOF-MS) and database analysis.
RESULTS
1. The model of hyperensive rats with hyperactivity of liver-yangwere reproduced succeedly, and the curative effect of Pinggan-Qianyang treatment was good.
2. The 2-DE Patterns of hypothalamuses and adrenal glands of normal rats、SHR with hyperactivity of liver-yang and the rats with hyperactivity of liver-yang with Pinggan-Qianyang treatment were presented.Gel-image analysis reveals that there are 27 differential protein spots.
3. The 22 of total 25 differential protein spots are successfully identified by MALDI-TOF-MS.The functions of these Proteins involve in metabolism, energy generation, transportation, antioxidation, sigal transduction and cytoskeleton etc according to information provided in NCBI and MSDB database. Among them, there are some proteins closely related to hypertension with hyperactivity of liver-yang and the Pinggan-Qianyang treatment, such as Peroxirdoxin-II、Heat shockprotein-27、Annexin-A1.
CONCLUSION
The blood pressure of hyperensive rats with hyperactivity ofliver-yang is reduced with symptoms ameliorated after taking Pinggan-Qianyang treatment, which might be related to the changes of hypothalamic and adrenergdrenic protein. Appreciated hypothalamic and adrenergdrenic differential expressed proteins with Pinggan-Qianyang treatment succeedly. This approachmay lay a foundation for the further investigation of pathogenic mechanisms in hypertension with hyperactivity of liver-yang and curative effect mechanisms of Pinggan-Qianyang treatment.
引文
[1]刘忠仁.我国各地高血压流行病学调查近况.医学综述,2004,10(2):88-89
[2]王薇,赵冬.中国老年人高血压的流行病学.中华老年医学杂志,2005,24(4):246-247
[3]Chobanian AV,Bakris GL,Black HR,et al.The seventh report of t he joint national committee on prevention,detection,evaluation,and treatment of high blood pressure:the JNC 7 report[J].JAMA,2003,289:2560-2572
[4]胡小燕.中医辨证分型选用抗高血压药的临床研究[J].辽宁中医药大学学报,2006,8(15):95
[5]陈明嘉.高血压病(肝阳上亢型)的中医治疗及研究近况.中医药导报,2006,12(1):80-82
[6]陈华德,方针,王狲敏.高血压病肝阳上亢证的研究进展.中国中医药信息杂志,2004,11(2):178-180
[7]胡小勤,陈利国.中医药治疗高血压病作用机制的研究进展.中华中医药杂志,2006,21(10):612-613
[8]KuboT,Hagiwara Y.Protein kinase C activation- induced increases of neural activity are enhanced in hypothalamus of spontanously hypertensive rats.Brain Res,2005,1033(2):157-163
[9]FISHER S J,BRUNING J C,LANNON S,et al.Insuling signaling in the central nervous systerm is critical for the normal sympathoadrenal response to hypoglycemia[J].diabetes,2005,54(5):1447-1451
[10]张露青,左国平,丁炯.加压素在自发性高血压病大鼠与正常大鼠下丘脑视上核、室旁核神经元内表达.解剖科学进展,2005,11(3):213-215
[11]王红梅,李南方.β3肾上腺素能受体基因多态性与胰岛素抵抗、高血压病关系的研究进展.国际遗传学杂志,2007,30(2):140-142
[12]杨兴才.高血压病肝阳上亢证型的客观化研究.北京中医,2005,24(1):58-60
[13]韦玮,龙春莉,方显明.天麻钩藤饮治疗高血压病的研究进展.浙江中医杂志,2007,42(1):54-57
[14]Pandey A,Mann M.Proteomics to study genes and genomes.Nature,2000,405(6788):837-846
[15]金光亮.证候基因组学与证候蛋白质组学浅论[J].中医药学报,2003, 18(6):332-335
[16]鄢东红,金益强,肖纯,等.自发性高血压大鼠肝阳上亢证模型的复制.湖南中医学院学报,1999,19(4):35-38
[17]杨绿化,邹沙舟,李云霞.无创测量大鼠收缩压和舒张压的新仪器和新方法.中国应用生理学杂志,1991,7(1):62-64
[18]刘力生,龚兰生.中国高血压防治指南[M].北京:人民卫生出版社,2005年修订版,2005:5-6
[19]阎菊,李国臣.中西医结合治疗高血压病的临床思考[J].现代中医药,2004,4:32-33
[20]周文献.中西医结合治疗高血压病的思考与探索[J].河南中医药学刊,2001,6(16):29-30
[21]毕媛媛,段学忠,刘易宗.中医药治疗高血压病的机制研究进展.现代中西医结合杂志,2008,17(7):1125-1126
[22]廖圣保,李靓,丁荣光.高血压病中医治法浅述.中国医药学报,2002,17(6):359-361
[23]宋纯清,樊懿,黄伟晖,等.钩藤中不同成分降压作用的差异[J].中草药,2000,31(10):762-764
[24]Gorbtt JM,Dunn MJ,Posch A,t al.Positional reproducibility of protein spots in two-dimensional polyacrylamide electrophoresis using immobilised pH gradient isoelectric focusing in the first dimension:an interlaboratory comparison[J].Electrophoresis,1994,15::1205-1211
[25]李航,黎乐群,万里凯,等.1,6-二磷酸果糖醛缩酶对无水酒精注射治疗原发性肝癌中的观察中国肿瘤临床,2004,31(6):309-311
[26]刘光慧,沈恂.硫氧还蛋白与心血管疾病.生物物理学报,2006,22(6):406-414
[27]Ebrahimian T,Touvz RM.Thioredoxin in vascular biology:role in hypertension.AntioxidRedox Signal,2008,10(6):1127-1136
[28]Lee CK,Kim HT,Lee YR,et al.Analysis of peroxiredoxin decreasing oxidative stress in hypertensive aortic smooth muscle.Biochim Biophys Acta,2007,1774(7):848-855
[29]Tvagi N,Moshal KS,Ovechkin AV,et al.Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia.J Cell Biochem,2005,96(4):665-671
[30]Martin- Ventura JL,Duran MC,Blanco- Colio LM,et al.Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis[J].Circulation,2004,110(15):2216- 2219
[31]廖明芳,崔佳森,张健,等.热休克蛋白27在人胸主动脉夹层的表达研究.中国现代普通外科进展,2007,10(5):393-397
[32]Terrier B,Tamby MC,Camoin L,et al.Identification of Target Antigens of Anti-fibroblast Antibodies in Pulmonary Arterial Hypertension.Am J Respir Crit Care Med,2008,14:1-3
[33]Andersen O,Pantopoulos K,Kao HT,et al.Regulation of iron metabolism in the sanguivore lamprey lampetra fluviatilis molecular cloning of two ferritin subunits and two iron-regulatory protein(IRP)reveals evolutionary conservation of the iron-regulatory element(IRE)/IRP regulatory system.Eur J Biochem,1998,254(2):223-228
[34]Cozzi A,Santambrogio P,Levi S,et al.Iron detoxifying activity of ferritin:effects of H and L human apoferritins on lipid peroxidationinvitro.FEBS Lett,1990,277(1-2):119-125
[35]Balla G,Jacob HS,Balla J,et al.Ferritin:a cytoprotective antioxidant strategem of endothelium.J Bio Chem,1992,267(25):1814-1820
[36]Erario MA,Gonzales S,Noriega GO,et al.Bilirubin and ferritin as protectors against hemin-induced oxidative stress in rat liver.Cell Mol Biol (Noisy-le-grand),2002,48(8):877-883
[37]Ishizaka N,Saito K,Mori I,et al.Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin Ⅱ-infused rats.Arterioscler Thromb Vasc Biol,2005,25(11):2235-2237
[38]Ishizaka N,Saito K,Noiri E,et al.Administration of ANG Ⅱ induces iron deposition and upregulation of TGF-betal mRNA in the rat liver.Am J Physiol Regul Integr Comp Physiol,2005,288(4):1063-1070
[39]Dusting GJ,Selemidis S,Jinang F.Mechanisms for suppressing NADPH oxidase in the vascular wall.Mem Inst Oswaldo Cruz,2005,100(11):97-103
[40]戴维国,马常升,马文领.脑缺血早期星形胶质细胞谷氨酰胺合成酶免疫组化的时程变化.解剖学杂志,2003,26(4):352-355
[41]Sahai E,Marshall CJ.Rho-GTPases and cancer[J].Nature Reviews Cancer,2002,2(1):133-142
[42]Gorvel JP,Chang TC,Boretto J,et al.Differential properties of D4/Ly GDI versus Rho-GDI:Phosphorylation and rho GTPase selectivity[J].FEBS,1998, 422(2):269-273
[43]Artemenko IP,Hales KH,Jefcoate CR,et al.Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein(STAR),but nottotal STAR,mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells[J].J Biol Chem,2001,276(49):46583-46590
[44]Krug AW,Vleugels K,Schinner S,et al.Human adipocytes induce an ERK1/2MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR)and an angiotensin Ⅱ - sensitization in human adrenocortical cells.International Journal of Obesity,2007,31:1605-1616
[45]Li QF,Dai AG.Differential expression of three hypoxia-inducible factor-alpha subunits in pulmonary arteries of rat with hypoxia-induced hypertension.Acta Biochim Biophys Sin(Shanghai),2005,37(10):665-672
[46]Touvz RM,He Y,Montezano AC,et al.Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG Ⅱ in vascular smooth muscle cells from spontaneously hypertensive rats.Am J Physiol Regul Integr Comp Physiol,2006,290(1):73-78
[47]曹云山,张 敏.Annexin A1与炎症、冠心病关系.国际病理科学与临床杂志,2005,25(4):311-313
[48]La M,D'Amico M,Bandiera S,et al.Annexin 1 pep tides protect against experimental myocardial ischemia-reperfusion:analysis of their mechanism of action[J].FASEB J,2001,15(12):2247-2256
[49]Chondrogianni N,Tzavelas C,Pemberton AJet al.Overexpression of proteasome beta 5 subunit increases amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates.Biol Chem,2005,280(12):11840-11850
[50]Morisco C,Lembo G,Trimarco B.Insulin resistance and cardiovascular risk:New insights from molecular and cellular biology.Trends Cardiovasc Med,2006,16(6):183-188
[51]Kruszewski K,Kalinowska J,Chabielska E,et al.Changes in proteasome activity in the ischemic kidney of rat with experimental renovascular hypertension.Rocz Akad Med Bialymst,2004,49(11):252-254
[52]Ostrowska H,Kxuszewski K,Kasacka I.Immuno-proteasome subunit LMP7 is up-regulated in the ischemic kidney in an experimental model of renovascular hypertension.Int J Biochem Cell Biol,2006,38(10):1778-1785
[53]Vinkenoog R,Speranca MA,Breemen OV,et al.Malaria para-sites contain two identical copies of an elongation factor 1 alpha gene[J].Molecular and Biochemical Parasitology,1998,94:1-12
[54]Woriax V,Bullard M J,Ma L,et al.Mechanistic study of the translational elongation cycle in mammol/Lalian mitochondria[J].Biochim Biophys Acta,1997,1352(1):91-101
[55]Slobin LI.The role of eukaryotic elongation factor Tu in protein synthesis[J].Eur J Biochem,1980,110:555-563
[1]刘忠仁.我国各地高血压流行病学调查近况.医学综述,2004,10(2):88-89
[2]王薇,赵冬.中国老年人高血压的流行病学.中华老年医学杂志.2005,24(4):246-247
[3]周忠明,赵崇学.浅析高血压与肝阳上亢的关系.陕西中医,2007,28(6):766-767
[4]陈明嘉.高血压病(肝阳上亢型)的中医治疗及研究近况.中医药导报,2006,12(1):80-82
[5]王海霞.肝阳上亢证中医文献研究.内蒙古中医药,2007,6:47-49.
[6]曹淞申,李培群.高血压病患者左心室质量的超声心动图观察及其与中医分型的关系.中国中西医结合杂志,1997,15(3):171-172
[7]段开骏,刘洁,白春锦.不同中医辨证分型的高血压患者左心结构和功能指标变化.中国临床康复,2006,10(3):51-54
[8]朱国强.高血压病的证型与心脏收缩舒张功能的关系.实用中医内科杂志,2003,17(6):475-477
[9]郑新,刘卫红.原发性高血压中医辨证分型的血压变化及胸主动脉CT 改变的研究.中国中西医结合杂志,1997,17(12):733-734
[10]王小娟,李冰星,郭建生.脉图参数变化与原发性高血压的分期及辨证关系研究[J].中国中医基础医学杂志,2000,6(9):45-47
[11]赵泽红,张玉亮,范翎翎,等.高血压患者靶器官损害与血压昼夜节律及中医证型的关系[J].中医杂志,2004,42(12):741-743
[12]夏大胜,尤劲松,胡随瑜.原发性高血压肝阳上亢证、肝肾阴虚证患者动态血压分析[J].湖南医科大学学报,2000,25(2):149-152
[13]张世亮,门雪琳.高血压病不同中医证型与24 h动态血压关系的研究[J].山东中医药大学学报,2003,27(2):115-116
[14]赵肖华,帕力旦,陈红霞.高血压病动态血压与中医辨证分型的关系.新疆中医药,2006,24(4):23-24
[15]郑琼莉,祝炜,王超.顽固性高血压病人中医证型及血压形态特点分析.中西医结合心脑血管杂志,2007,5(3):193-194
[16]龚一萍,连怡绍,陈素珍.常见病理舌色定量研究及与疾病和证型相关性分析.中国中医药信息杂志,2005,12(7):20-21
[17]龚一萍,陈海燕,卜佳俊.常见病理舌形的定量研究及与高血压病和证型相关性的分析.中华中医药杂志,2005,20(12):730-731
[18]周勇,龚一萍,连怡绍.高血压病不同证型胖瘦舌、点刺舌的计算机定量研究.中医药学报,2007,35(2):28-30
[19]郝芳.中医多种证型眩晕的经颅多普勒观察研究.辽宁中医杂志,2007,34(4):482-483
[20]黄玉贞,潘光明,许艳.高血压病患者中医辨证分型与经颅多普勒的关系.辽宁中医杂志,2007,34(6):710-711
[21]刘泽银,邹旭,严夏.原发性高血压病不同证型与左室舒张功能不全 的关系.新中医,2003,35(1):38-40
[22]任敏之,符德玉,颜乾麟.高血压病患者中医证型与靶器官损害关系的临床研究.四川中医,2006,24(9):47-48
[23]王宗繁,高大运,胡秋华.对高血压病人不同证型心肌耗氧指数变化的实验观察.医学理论与实践,1999,12(8):440-441
[24]王莉娅,张婕,朱丽华,等.高血压病患者P波终末电势与中医证型的关系.南京中医药大学学报(自然科学版),2000,16(1):20-22
[25]姜奥.高血压病不同中医证型与心率变异相关性的研究.中西医结合心脑血管杂志,2005,3(1):13-14
[26]王英杰,胡婉英.原发性高血压病病人血管重构与中医证型相关关系的研究.中西医结合心脑血管病杂志,2007,5(1):11-13
[27]段开骏,刘洁,白春锦.不同中医辨证分型的高血压患者颈动脉血管重构变化.中医药学刊,2006,24(5):893-896
[28]陈国英,刘德桓,向成彬.高血压病中医证型与脑卒中神经功能缺损程度的相关性研究.中华中医药学刊,2008,26(2):370-372
[29]丁碧云,邵正斌,郑林.原发性高血压早期肾损害与中医证型的相关性研究.安徽中医学院学报,2006,25(4):6-9
[30]曾晓琼,刘淘真,邓毅.老年原发性高血压脉压与脑血流动力学变化关系的研究.实用老年医学,2002,16(5):244-246
[31]邢俊武,钱士明.高血压患者的外周微循环变化[J].现代中西医结合志,2003,12(1):58-59
[32]胡随瑜,金益强,张翔,等.肝阳上亢证实验诊断指标研究[J].中医杂志,2000,39(11):680-682
[33]张世亮,普晓明.高血压病眩晕中医证型与脑超声多普勒血流图关系的研究.山东中医药大学学报,2003,27(5):354-355
[34]黄炎明,何世银.高血压病患者红细胞免疫功能及其与血瘀证关系的研究[J].同济医科大学学报,2001,23(6):517
[35]李权,李艳.原发性高血压患者红细胞内钙和红细胞变形性.微循环学杂志,2003,13(4):61-63
[36]赵津辉,杨利军,王翠平,等.高血压人群及正常人群血流变学指标变化的实验研究.现代中西医结合杂志,2000,9(18):1752
[37]侯延丽.123例高血压病血液流变学变化与中医辨证分型的关系.陕西中医,2002,23(8):703-704
[38]毛莉娜,祝炜,喻荣辉.高血压病中医证型与血液流变学及胰岛素抵抗 的相关性研究.湖北中医学院学报,2007,9(2):24-25
[39]白春锦,周瀛,王丽,等.不同中医证型高血压患者的心血管危险因素分层、高血压分期、分级及血脂等指标变化特征.中国临床康复,2005,9(23):145-147
[40]李泓,卜秦利,胡蕴.原发性高血压肾素、血管紧张素Ⅱ、醛固酮及血浆心纳素水平与辨证分型关系[J].中西医结合杂志,1991,11(5):271-273
[41]杨红,金艳蓉,杨海燕.高血压病血脂异常与辨证分型的关系.疑难病杂志,2002,1(4):221-223
[42]张建丽,叶德平.高血压病血脂异常与中医辨证分型关系探讨.河北中医,2005,27(4):264-265
[43]梁东辉,张敏,李小敏,等.高血压病中医辨证分型与血脂水平关系的探讨[J].辽宁中医杂志,1996,23(4):148-150
[44]刘丽萍.不同中医证型高血压患者血生化指标与肥胖相关因素的差异.中国临床康复,2006,10(15):12-13
[45]黄晓丽,张新军,张晓军,等.老年高血压病人血浆纤维蛋白原和血小板聚集功能的观察[J].四川医学,2004,25(2):144-145
[46]李刚.高血压病病人不同血压分级与血浆内皮素和降钙素相关基因相关肽的关系探讨[J].中国现代医学杂志,2004,14(3):75-76
[47]陶连方.老年高血压病糖尿病患者血浆内皮素测定及其意义.中国微循环,2003,7(4):245-247
[48]陈金秒,杨利军,吕建设,等.不同证型原发性高血压患者血浆内皮素和血小板α-颗粒膜蛋白含量的实验研究[J].现代中西医结合杂志,2000,9(18):1751-1752
[49]辛效毅,张绚邦,周铭心.血浆内皮素和血管紧张素Ⅱ水平与高血压病辨证分型关系的临床意义.中国中西医结合杂志,2002,22(11):830
[50]郑峰,胡世云,孙 光,等.Ⅱ期原发性高血压中医证型与血浆内皮素一氧化氮关系的临床研究[J].福建中医药,2000,31(2):5-7
[51]陈正贵,孔祥廉,缪灿铭.高血压患者血压昼夜节律消失与一氧化氮和内皮素关系的研究.中国医师杂志,2006,8(10):1345-1347
[52]张臣,邢之华,刘卫平.高血压病中医证型与血浆内皮素及血压的相关性研究.辽宁中医杂志,2005,32(1):6-7
[53]何光明,傅美琴,涂华中.高血压病“肝亢血瘀”证的探讨[J].陕西中医,2001,22(2):93-94
[54]徐树楠,张再康.从瘀论治高血压病探讨[J].中国中医基础医学杂志, 2004,10(8):35-38
[55]郑林,王学岭,杜武勋.高血压病肝阳上亢证与血瘀病机的相关研究[J].天津中医,2002,19(3):14-16
[56]王爱珍,蔡治宾,吴罗杰.原发性高血压病中医辨证分型与肾素、血管紧张素初探.中国现代医学杂志,1998,8(5):43-45
[57]辛效毅,张绚邦,周铭心.血浆Ag Ⅱ、CGRP水平与高血压病患者辨证分型的关系.贵阳中医学院学报,2002,24(1):49-51
[58]辛效毅,张绚邦,周铭心.高血压病中医证型与血浆ET、AgⅡ关系研究.山东中医药大学学报,2002,26(2):123-125
[59]鄢东红,金益强,李学文,等.高血压病同病异证血浆血管紧张素Ⅱ含量的研究[J].中国现代医学杂志,1998,8(11):37-38
[60]金益强,胡随瑜,鄢东红,等.高血压肝阳上亢证的分子机理研究[J].中国中西医结合杂志,2000,20(2):87-90
[61]高喜源,包桂英,张雪峰.高血压病中医辨证与血浆心钠素、肾素血管紧张素醛固酮系统的相关性研究.中国中医药科技,2007,14(6):386-389
[62]张志斌,陆曙,李萍.甲状腺激素水平与原发性高血压及其中医证型的相关性研究.现代中西医结合杂志,2008,17(4):490-493
[63]叶德寿,李东野,李英,等.胰岛素抵抗与高血压病关系流行病学研究[J].心血管康复医学杂志,2005,14(6):543-545
[64]蒋卫民,唐蜀华,陈晓虎.高血压病辨证分型与胰岛素抵抗关系的初步研究[J].中国中医基础医学杂志,2001,4(11):37-40
[65]张玉金,张文芳.高血压病辨证分型和胰岛素抵抗关系的探讨[J].河南中医,2001,21(1):35-38
[66]沈毅,张继东.原发性高血压病中医辨证分型与胰岛素抵抗的相关性研究[J].山东大学学报(医学版),2005,43(2):143-144
[67]吴启锋,熊尚全,温茂详,等.高血压病中医证型与盐敏感性及胰岛素抵抗关系临床研究[J].福建中医药,2002,33(3):35-38
[68]王岳屏,严颂琴,彭国顺.高血压病病人不同证候与糖脂肪代谢及瘦素水平的关系.中西医结合心脑血管病杂志,2007,5(6):476-478
[69]王芸素,陈宏桂.高血压病辨证分型与胰岛素抵抗的关系[J].中西医结合心脑血管病杂志,2004,2(10):611-614
[70]马民,陈利国.血瘀证病人血小板CD62p基因、白细胞HSP70基因的表达[J].中国中西医结合杂志,2005,25(4):307-310
[71]宋津晓,刘美霞,刘洪英.低密度脂蛋白受体基因多态性与高血压关系的 研究.河北医科大学学报,2006,27(6):528-530
[72]王光平,金益强,鄢东红.应用信使核糖体核酸差异显示研究中医肝阳上亢、肝阳化风证的基因表达[J].南京中医学院学报,2001,21(1):65-68
[73]谌兵来,唐发清,金益强,等.高血压病肝阳上亢证酪氨酸羟化酶及单胺氧化酶微卫星多态性分析[J].湖南中医学院学报,2000,20(1):37-38
[74]卢全生,雷燕,陈可冀.AT1R基因多态性与原发性高血压中医证型及降压中药疗效的关系.中国中西医结合杂志,2005,25(8):682-686
[75]Pandey A,Mann M.Proteomics to study genes and genomes.Nature,2000,405(6788):837-846
[76]熊新贵,梁清华,侯俊良,等.高血压脑出血肝阳化风证与肝阳上亢证患者血清蛋白质组学研究.实用预防医学,2007,14(6):1649-1652
[77]颜永平,易振佳,李炜,等.高血压大鼠肝阳上亢证的下丘脑双向凝胶电泳分析.中国医师杂志,2006,8(3):330-333
[78]张娴,曾星,段小军,等.高血压肝阳上亢证大鼠模型建立和蛋白质表达分析.四川中医,2008,26(3):9-11
[79]李臻琰,李炜,颜永平,等.天麻钩藤饮对高血压肝阳上亢证大鼠下丘脑差异蛋白质表达的影响.中国临床康复,2006,10(47):58-61
[80]王素娥,李臻琰,钟广伟,等.天麻钩藤饮对高血压肝阳上亢证大鼠肾上腺蛋白质的影响中医药导报,2008,14(1):12-15
[81]丘志春.我院高血压中医处方统计分析[J].中医药导报,2005,11(5):52
[82]黄观灵.镇肝熄风汤加减治疗肝阳上亢高血压56例[J].现代中西医结合杂志,2001,10(10):147-149
[83]谭荣斌.原发性高血压病中医辨证治疗.中国实用医药,2008,3(6):62-63
[84]张艳,柳士博,庞敏.高血压病的中医辨证治疗.中国实用乡村医生杂志,2007,14(10):11-12
[85]杨辉.中西医结合治疗高血压病眩晕34例[J].中国民间疗法,2004,12(7):5
[86]魏霞.高血压辨证体会[J].中国医药报,2004,19(1):59
[87]邓娟.自拟平肝降压汤治疗高血压病60例临床观察[J].北京中医,2003,10(22):29-30
[88]赵东杰.针刺对高血压病胰岛素抵抗的影响[J].中国针灸,2003,23(3):165-167
[89]吴清明,冯国湘,汤雪飞.针刺开“四关”加百会穴温针灸对原发性高血压病人血浆中ET和NO的影响[J].中国针灸,2004,24(1):53-55
[90]邢孝民,黄志华,房玉珍.平肝潜阳针法对原发性高血压病人甲襞微循环的影响[J].中国临床康复,2005,9(7):106-107
[91]彭丽辉,冯玲媚,陈筑芳,等.艾灸对高血压病患者血压及NO、ET、SOD、MDA的影响[J].中国针灸,2004,24(3):157-159
[92]王宁,张昆,郑君.隔芪香散灸脐法治疗高血压肝阳上亢证30例.四川中医,2007,25(4):60-61
[93]张昆,郑君,王宁.隔药灸脐法治疗高血压肝阳上亢证30例.浙江中医杂志,2007,42f7):417-419
[94]陈华德,方针,王翀敏.耳尖放血治疗高血压病肝阳上亢证疗效观察[J].中国针灸,2004,24(4):229-231
[95]陈华德.耳尖放血疗法改善高血压病肝阳上亢证.中国社区医师,2006,22(312):30
[96]汤日鹏,宋顺福,周克义,等.耳尖放血疗法治疗高血压病肝阳上亢证临床观察.中医药学刊,2006,24(12):2219
[97]黄淑芳,梁纪文.高血压病的中医综合治疗.中国临床医生,2006,34(10):15-16
[98]匡海茜.耳穴贴压治疗原发性高血压100例[J].潍坊医学院学报,2004,26(5):94
[99]商翠莲.吴茱萸敷神阙穴治疗高血压60例[J].中医外治杂志,2003,12(2):46
[100]黄小平.五子散外敷涌泉穴对高血压昼夜杰律影响临床观察[J].按摩与导引,2004,20(3):25-27
[2]王薇,赵冬.中国老年人高血压的流行病学.中华老年医学杂志,2005,24(4):246-247
[3]Chobanian AV,Bakris GL,Black HR,et al.The seventh report of t he joint national committee on prevention,detection,evaluation,and treatment of high blood pressure:the JNC 7 report[J].JAMA,2003,289:2560-2572
[4]胡小燕.中医辨证分型选用抗高血压药的临床研究[J].辽宁中医药大学学报,2006,8(15):95
[5]陈明嘉.高血压病(肝阳上亢型)的中医治疗及研究近况.中医药导报,2006,12(1):80-82
[6]陈华德,方针,王狲敏.高血压病肝阳上亢证的研究进展.中国中医药信息杂志,2004,11(2):178-180
[7]胡小勤,陈利国.中医药治疗高血压病作用机制的研究进展.中华中医药杂志,2006,21(10):612-613
[8]KuboT,Hagiwara Y.Protein kinase C activation- induced increases of neural activity are enhanced in hypothalamus of spontanously hypertensive rats.Brain Res,2005,1033(2):157-163
[9]FISHER S J,BRUNING J C,LANNON S,et al.Insuling signaling in the central nervous systerm is critical for the normal sympathoadrenal response to hypoglycemia[J].diabetes,2005,54(5):1447-1451
[10]张露青,左国平,丁炯.加压素在自发性高血压病大鼠与正常大鼠下丘脑视上核、室旁核神经元内表达.解剖科学进展,2005,11(3):213-215
[11]王红梅,李南方.β3肾上腺素能受体基因多态性与胰岛素抵抗、高血压病关系的研究进展.国际遗传学杂志,2007,30(2):140-142
[12]杨兴才.高血压病肝阳上亢证型的客观化研究.北京中医,2005,24(1):58-60
[13]韦玮,龙春莉,方显明.天麻钩藤饮治疗高血压病的研究进展.浙江中医杂志,2007,42(1):54-57
[14]Pandey A,Mann M.Proteomics to study genes and genomes.Nature,2000,405(6788):837-846
[15]金光亮.证候基因组学与证候蛋白质组学浅论[J].中医药学报,2003, 18(6):332-335
[16]鄢东红,金益强,肖纯,等.自发性高血压大鼠肝阳上亢证模型的复制.湖南中医学院学报,1999,19(4):35-38
[17]杨绿化,邹沙舟,李云霞.无创测量大鼠收缩压和舒张压的新仪器和新方法.中国应用生理学杂志,1991,7(1):62-64
[18]刘力生,龚兰生.中国高血压防治指南[M].北京:人民卫生出版社,2005年修订版,2005:5-6
[19]阎菊,李国臣.中西医结合治疗高血压病的临床思考[J].现代中医药,2004,4:32-33
[20]周文献.中西医结合治疗高血压病的思考与探索[J].河南中医药学刊,2001,6(16):29-30
[21]毕媛媛,段学忠,刘易宗.中医药治疗高血压病的机制研究进展.现代中西医结合杂志,2008,17(7):1125-1126
[22]廖圣保,李靓,丁荣光.高血压病中医治法浅述.中国医药学报,2002,17(6):359-361
[23]宋纯清,樊懿,黄伟晖,等.钩藤中不同成分降压作用的差异[J].中草药,2000,31(10):762-764
[24]Gorbtt JM,Dunn MJ,Posch A,t al.Positional reproducibility of protein spots in two-dimensional polyacrylamide electrophoresis using immobilised pH gradient isoelectric focusing in the first dimension:an interlaboratory comparison[J].Electrophoresis,1994,15::1205-1211
[25]李航,黎乐群,万里凯,等.1,6-二磷酸果糖醛缩酶对无水酒精注射治疗原发性肝癌中的观察中国肿瘤临床,2004,31(6):309-311
[26]刘光慧,沈恂.硫氧还蛋白与心血管疾病.生物物理学报,2006,22(6):406-414
[27]Ebrahimian T,Touvz RM.Thioredoxin in vascular biology:role in hypertension.AntioxidRedox Signal,2008,10(6):1127-1136
[28]Lee CK,Kim HT,Lee YR,et al.Analysis of peroxiredoxin decreasing oxidative stress in hypertensive aortic smooth muscle.Biochim Biophys Acta,2007,1774(7):848-855
[29]Tvagi N,Moshal KS,Ovechkin AV,et al.Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia.J Cell Biochem,2005,96(4):665-671
[30]Martin- Ventura JL,Duran MC,Blanco- Colio LM,et al.Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis[J].Circulation,2004,110(15):2216- 2219
[31]廖明芳,崔佳森,张健,等.热休克蛋白27在人胸主动脉夹层的表达研究.中国现代普通外科进展,2007,10(5):393-397
[32]Terrier B,Tamby MC,Camoin L,et al.Identification of Target Antigens of Anti-fibroblast Antibodies in Pulmonary Arterial Hypertension.Am J Respir Crit Care Med,2008,14:1-3
[33]Andersen O,Pantopoulos K,Kao HT,et al.Regulation of iron metabolism in the sanguivore lamprey lampetra fluviatilis molecular cloning of two ferritin subunits and two iron-regulatory protein(IRP)reveals evolutionary conservation of the iron-regulatory element(IRE)/IRP regulatory system.Eur J Biochem,1998,254(2):223-228
[34]Cozzi A,Santambrogio P,Levi S,et al.Iron detoxifying activity of ferritin:effects of H and L human apoferritins on lipid peroxidationinvitro.FEBS Lett,1990,277(1-2):119-125
[35]Balla G,Jacob HS,Balla J,et al.Ferritin:a cytoprotective antioxidant strategem of endothelium.J Bio Chem,1992,267(25):1814-1820
[36]Erario MA,Gonzales S,Noriega GO,et al.Bilirubin and ferritin as protectors against hemin-induced oxidative stress in rat liver.Cell Mol Biol (Noisy-le-grand),2002,48(8):877-883
[37]Ishizaka N,Saito K,Mori I,et al.Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin Ⅱ-infused rats.Arterioscler Thromb Vasc Biol,2005,25(11):2235-2237
[38]Ishizaka N,Saito K,Noiri E,et al.Administration of ANG Ⅱ induces iron deposition and upregulation of TGF-betal mRNA in the rat liver.Am J Physiol Regul Integr Comp Physiol,2005,288(4):1063-1070
[39]Dusting GJ,Selemidis S,Jinang F.Mechanisms for suppressing NADPH oxidase in the vascular wall.Mem Inst Oswaldo Cruz,2005,100(11):97-103
[40]戴维国,马常升,马文领.脑缺血早期星形胶质细胞谷氨酰胺合成酶免疫组化的时程变化.解剖学杂志,2003,26(4):352-355
[41]Sahai E,Marshall CJ.Rho-GTPases and cancer[J].Nature Reviews Cancer,2002,2(1):133-142
[42]Gorvel JP,Chang TC,Boretto J,et al.Differential properties of D4/Ly GDI versus Rho-GDI:Phosphorylation and rho GTPase selectivity[J].FEBS,1998, 422(2):269-273
[43]Artemenko IP,Hales KH,Jefcoate CR,et al.Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein(STAR),but nottotal STAR,mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells[J].J Biol Chem,2001,276(49):46583-46590
[44]Krug AW,Vleugels K,Schinner S,et al.Human adipocytes induce an ERK1/2MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR)and an angiotensin Ⅱ - sensitization in human adrenocortical cells.International Journal of Obesity,2007,31:1605-1616
[45]Li QF,Dai AG.Differential expression of three hypoxia-inducible factor-alpha subunits in pulmonary arteries of rat with hypoxia-induced hypertension.Acta Biochim Biophys Sin(Shanghai),2005,37(10):665-672
[46]Touvz RM,He Y,Montezano AC,et al.Differential regulation of transient receptor potential melastatin 6 and 7 cation channels by ANG Ⅱ in vascular smooth muscle cells from spontaneously hypertensive rats.Am J Physiol Regul Integr Comp Physiol,2006,290(1):73-78
[47]曹云山,张 敏.Annexin A1与炎症、冠心病关系.国际病理科学与临床杂志,2005,25(4):311-313
[48]La M,D'Amico M,Bandiera S,et al.Annexin 1 pep tides protect against experimental myocardial ischemia-reperfusion:analysis of their mechanism of action[J].FASEB J,2001,15(12):2247-2256
[49]Chondrogianni N,Tzavelas C,Pemberton AJet al.Overexpression of proteasome beta 5 subunit increases amount of assembled proteasome and confers ameliorated response to oxidative stress and higher survival rates.Biol Chem,2005,280(12):11840-11850
[50]Morisco C,Lembo G,Trimarco B.Insulin resistance and cardiovascular risk:New insights from molecular and cellular biology.Trends Cardiovasc Med,2006,16(6):183-188
[51]Kruszewski K,Kalinowska J,Chabielska E,et al.Changes in proteasome activity in the ischemic kidney of rat with experimental renovascular hypertension.Rocz Akad Med Bialymst,2004,49(11):252-254
[52]Ostrowska H,Kxuszewski K,Kasacka I.Immuno-proteasome subunit LMP7 is up-regulated in the ischemic kidney in an experimental model of renovascular hypertension.Int J Biochem Cell Biol,2006,38(10):1778-1785
[53]Vinkenoog R,Speranca MA,Breemen OV,et al.Malaria para-sites contain two identical copies of an elongation factor 1 alpha gene[J].Molecular and Biochemical Parasitology,1998,94:1-12
[54]Woriax V,Bullard M J,Ma L,et al.Mechanistic study of the translational elongation cycle in mammol/Lalian mitochondria[J].Biochim Biophys Acta,1997,1352(1):91-101
[55]Slobin LI.The role of eukaryotic elongation factor Tu in protein synthesis[J].Eur J Biochem,1980,110:555-563
[1]刘忠仁.我国各地高血压流行病学调查近况.医学综述,2004,10(2):88-89
[2]王薇,赵冬.中国老年人高血压的流行病学.中华老年医学杂志.2005,24(4):246-247
[3]周忠明,赵崇学.浅析高血压与肝阳上亢的关系.陕西中医,2007,28(6):766-767
[4]陈明嘉.高血压病(肝阳上亢型)的中医治疗及研究近况.中医药导报,2006,12(1):80-82
[5]王海霞.肝阳上亢证中医文献研究.内蒙古中医药,2007,6:47-49.
[6]曹淞申,李培群.高血压病患者左心室质量的超声心动图观察及其与中医分型的关系.中国中西医结合杂志,1997,15(3):171-172
[7]段开骏,刘洁,白春锦.不同中医辨证分型的高血压患者左心结构和功能指标变化.中国临床康复,2006,10(3):51-54
[8]朱国强.高血压病的证型与心脏收缩舒张功能的关系.实用中医内科杂志,2003,17(6):475-477
[9]郑新,刘卫红.原发性高血压中医辨证分型的血压变化及胸主动脉CT 改变的研究.中国中西医结合杂志,1997,17(12):733-734
[10]王小娟,李冰星,郭建生.脉图参数变化与原发性高血压的分期及辨证关系研究[J].中国中医基础医学杂志,2000,6(9):45-47
[11]赵泽红,张玉亮,范翎翎,等.高血压患者靶器官损害与血压昼夜节律及中医证型的关系[J].中医杂志,2004,42(12):741-743
[12]夏大胜,尤劲松,胡随瑜.原发性高血压肝阳上亢证、肝肾阴虚证患者动态血压分析[J].湖南医科大学学报,2000,25(2):149-152
[13]张世亮,门雪琳.高血压病不同中医证型与24 h动态血压关系的研究[J].山东中医药大学学报,2003,27(2):115-116
[14]赵肖华,帕力旦,陈红霞.高血压病动态血压与中医辨证分型的关系.新疆中医药,2006,24(4):23-24
[15]郑琼莉,祝炜,王超.顽固性高血压病人中医证型及血压形态特点分析.中西医结合心脑血管杂志,2007,5(3):193-194
[16]龚一萍,连怡绍,陈素珍.常见病理舌色定量研究及与疾病和证型相关性分析.中国中医药信息杂志,2005,12(7):20-21
[17]龚一萍,陈海燕,卜佳俊.常见病理舌形的定量研究及与高血压病和证型相关性的分析.中华中医药杂志,2005,20(12):730-731
[18]周勇,龚一萍,连怡绍.高血压病不同证型胖瘦舌、点刺舌的计算机定量研究.中医药学报,2007,35(2):28-30
[19]郝芳.中医多种证型眩晕的经颅多普勒观察研究.辽宁中医杂志,2007,34(4):482-483
[20]黄玉贞,潘光明,许艳.高血压病患者中医辨证分型与经颅多普勒的关系.辽宁中医杂志,2007,34(6):710-711
[21]刘泽银,邹旭,严夏.原发性高血压病不同证型与左室舒张功能不全 的关系.新中医,2003,35(1):38-40
[22]任敏之,符德玉,颜乾麟.高血压病患者中医证型与靶器官损害关系的临床研究.四川中医,2006,24(9):47-48
[23]王宗繁,高大运,胡秋华.对高血压病人不同证型心肌耗氧指数变化的实验观察.医学理论与实践,1999,12(8):440-441
[24]王莉娅,张婕,朱丽华,等.高血压病患者P波终末电势与中医证型的关系.南京中医药大学学报(自然科学版),2000,16(1):20-22
[25]姜奥.高血压病不同中医证型与心率变异相关性的研究.中西医结合心脑血管杂志,2005,3(1):13-14
[26]王英杰,胡婉英.原发性高血压病病人血管重构与中医证型相关关系的研究.中西医结合心脑血管病杂志,2007,5(1):11-13
[27]段开骏,刘洁,白春锦.不同中医辨证分型的高血压患者颈动脉血管重构变化.中医药学刊,2006,24(5):893-896
[28]陈国英,刘德桓,向成彬.高血压病中医证型与脑卒中神经功能缺损程度的相关性研究.中华中医药学刊,2008,26(2):370-372
[29]丁碧云,邵正斌,郑林.原发性高血压早期肾损害与中医证型的相关性研究.安徽中医学院学报,2006,25(4):6-9
[30]曾晓琼,刘淘真,邓毅.老年原发性高血压脉压与脑血流动力学变化关系的研究.实用老年医学,2002,16(5):244-246
[31]邢俊武,钱士明.高血压患者的外周微循环变化[J].现代中西医结合志,2003,12(1):58-59
[32]胡随瑜,金益强,张翔,等.肝阳上亢证实验诊断指标研究[J].中医杂志,2000,39(11):680-682
[33]张世亮,普晓明.高血压病眩晕中医证型与脑超声多普勒血流图关系的研究.山东中医药大学学报,2003,27(5):354-355
[34]黄炎明,何世银.高血压病患者红细胞免疫功能及其与血瘀证关系的研究[J].同济医科大学学报,2001,23(6):517
[35]李权,李艳.原发性高血压患者红细胞内钙和红细胞变形性.微循环学杂志,2003,13(4):61-63
[36]赵津辉,杨利军,王翠平,等.高血压人群及正常人群血流变学指标变化的实验研究.现代中西医结合杂志,2000,9(18):1752
[37]侯延丽.123例高血压病血液流变学变化与中医辨证分型的关系.陕西中医,2002,23(8):703-704
[38]毛莉娜,祝炜,喻荣辉.高血压病中医证型与血液流变学及胰岛素抵抗 的相关性研究.湖北中医学院学报,2007,9(2):24-25
[39]白春锦,周瀛,王丽,等.不同中医证型高血压患者的心血管危险因素分层、高血压分期、分级及血脂等指标变化特征.中国临床康复,2005,9(23):145-147
[40]李泓,卜秦利,胡蕴.原发性高血压肾素、血管紧张素Ⅱ、醛固酮及血浆心纳素水平与辨证分型关系[J].中西医结合杂志,1991,11(5):271-273
[41]杨红,金艳蓉,杨海燕.高血压病血脂异常与辨证分型的关系.疑难病杂志,2002,1(4):221-223
[42]张建丽,叶德平.高血压病血脂异常与中医辨证分型关系探讨.河北中医,2005,27(4):264-265
[43]梁东辉,张敏,李小敏,等.高血压病中医辨证分型与血脂水平关系的探讨[J].辽宁中医杂志,1996,23(4):148-150
[44]刘丽萍.不同中医证型高血压患者血生化指标与肥胖相关因素的差异.中国临床康复,2006,10(15):12-13
[45]黄晓丽,张新军,张晓军,等.老年高血压病人血浆纤维蛋白原和血小板聚集功能的观察[J].四川医学,2004,25(2):144-145
[46]李刚.高血压病病人不同血压分级与血浆内皮素和降钙素相关基因相关肽的关系探讨[J].中国现代医学杂志,2004,14(3):75-76
[47]陶连方.老年高血压病糖尿病患者血浆内皮素测定及其意义.中国微循环,2003,7(4):245-247
[48]陈金秒,杨利军,吕建设,等.不同证型原发性高血压患者血浆内皮素和血小板α-颗粒膜蛋白含量的实验研究[J].现代中西医结合杂志,2000,9(18):1751-1752
[49]辛效毅,张绚邦,周铭心.血浆内皮素和血管紧张素Ⅱ水平与高血压病辨证分型关系的临床意义.中国中西医结合杂志,2002,22(11):830
[50]郑峰,胡世云,孙 光,等.Ⅱ期原发性高血压中医证型与血浆内皮素一氧化氮关系的临床研究[J].福建中医药,2000,31(2):5-7
[51]陈正贵,孔祥廉,缪灿铭.高血压患者血压昼夜节律消失与一氧化氮和内皮素关系的研究.中国医师杂志,2006,8(10):1345-1347
[52]张臣,邢之华,刘卫平.高血压病中医证型与血浆内皮素及血压的相关性研究.辽宁中医杂志,2005,32(1):6-7
[53]何光明,傅美琴,涂华中.高血压病“肝亢血瘀”证的探讨[J].陕西中医,2001,22(2):93-94
[54]徐树楠,张再康.从瘀论治高血压病探讨[J].中国中医基础医学杂志, 2004,10(8):35-38
[55]郑林,王学岭,杜武勋.高血压病肝阳上亢证与血瘀病机的相关研究[J].天津中医,2002,19(3):14-16
[56]王爱珍,蔡治宾,吴罗杰.原发性高血压病中医辨证分型与肾素、血管紧张素初探.中国现代医学杂志,1998,8(5):43-45
[57]辛效毅,张绚邦,周铭心.血浆Ag Ⅱ、CGRP水平与高血压病患者辨证分型的关系.贵阳中医学院学报,2002,24(1):49-51
[58]辛效毅,张绚邦,周铭心.高血压病中医证型与血浆ET、AgⅡ关系研究.山东中医药大学学报,2002,26(2):123-125
[59]鄢东红,金益强,李学文,等.高血压病同病异证血浆血管紧张素Ⅱ含量的研究[J].中国现代医学杂志,1998,8(11):37-38
[60]金益强,胡随瑜,鄢东红,等.高血压肝阳上亢证的分子机理研究[J].中国中西医结合杂志,2000,20(2):87-90
[61]高喜源,包桂英,张雪峰.高血压病中医辨证与血浆心钠素、肾素血管紧张素醛固酮系统的相关性研究.中国中医药科技,2007,14(6):386-389
[62]张志斌,陆曙,李萍.甲状腺激素水平与原发性高血压及其中医证型的相关性研究.现代中西医结合杂志,2008,17(4):490-493
[63]叶德寿,李东野,李英,等.胰岛素抵抗与高血压病关系流行病学研究[J].心血管康复医学杂志,2005,14(6):543-545
[64]蒋卫民,唐蜀华,陈晓虎.高血压病辨证分型与胰岛素抵抗关系的初步研究[J].中国中医基础医学杂志,2001,4(11):37-40
[65]张玉金,张文芳.高血压病辨证分型和胰岛素抵抗关系的探讨[J].河南中医,2001,21(1):35-38
[66]沈毅,张继东.原发性高血压病中医辨证分型与胰岛素抵抗的相关性研究[J].山东大学学报(医学版),2005,43(2):143-144
[67]吴启锋,熊尚全,温茂详,等.高血压病中医证型与盐敏感性及胰岛素抵抗关系临床研究[J].福建中医药,2002,33(3):35-38
[68]王岳屏,严颂琴,彭国顺.高血压病病人不同证候与糖脂肪代谢及瘦素水平的关系.中西医结合心脑血管病杂志,2007,5(6):476-478
[69]王芸素,陈宏桂.高血压病辨证分型与胰岛素抵抗的关系[J].中西医结合心脑血管病杂志,2004,2(10):611-614
[70]马民,陈利国.血瘀证病人血小板CD62p基因、白细胞HSP70基因的表达[J].中国中西医结合杂志,2005,25(4):307-310
[71]宋津晓,刘美霞,刘洪英.低密度脂蛋白受体基因多态性与高血压关系的 研究.河北医科大学学报,2006,27(6):528-530
[72]王光平,金益强,鄢东红.应用信使核糖体核酸差异显示研究中医肝阳上亢、肝阳化风证的基因表达[J].南京中医学院学报,2001,21(1):65-68
[73]谌兵来,唐发清,金益强,等.高血压病肝阳上亢证酪氨酸羟化酶及单胺氧化酶微卫星多态性分析[J].湖南中医学院学报,2000,20(1):37-38
[74]卢全生,雷燕,陈可冀.AT1R基因多态性与原发性高血压中医证型及降压中药疗效的关系.中国中西医结合杂志,2005,25(8):682-686
[75]Pandey A,Mann M.Proteomics to study genes and genomes.Nature,2000,405(6788):837-846
[76]熊新贵,梁清华,侯俊良,等.高血压脑出血肝阳化风证与肝阳上亢证患者血清蛋白质组学研究.实用预防医学,2007,14(6):1649-1652
[77]颜永平,易振佳,李炜,等.高血压大鼠肝阳上亢证的下丘脑双向凝胶电泳分析.中国医师杂志,2006,8(3):330-333
[78]张娴,曾星,段小军,等.高血压肝阳上亢证大鼠模型建立和蛋白质表达分析.四川中医,2008,26(3):9-11
[79]李臻琰,李炜,颜永平,等.天麻钩藤饮对高血压肝阳上亢证大鼠下丘脑差异蛋白质表达的影响.中国临床康复,2006,10(47):58-61
[80]王素娥,李臻琰,钟广伟,等.天麻钩藤饮对高血压肝阳上亢证大鼠肾上腺蛋白质的影响中医药导报,2008,14(1):12-15
[81]丘志春.我院高血压中医处方统计分析[J].中医药导报,2005,11(5):52
[82]黄观灵.镇肝熄风汤加减治疗肝阳上亢高血压56例[J].现代中西医结合杂志,2001,10(10):147-149
[83]谭荣斌.原发性高血压病中医辨证治疗.中国实用医药,2008,3(6):62-63
[84]张艳,柳士博,庞敏.高血压病的中医辨证治疗.中国实用乡村医生杂志,2007,14(10):11-12
[85]杨辉.中西医结合治疗高血压病眩晕34例[J].中国民间疗法,2004,12(7):5
[86]魏霞.高血压辨证体会[J].中国医药报,2004,19(1):59
[87]邓娟.自拟平肝降压汤治疗高血压病60例临床观察[J].北京中医,2003,10(22):29-30
[88]赵东杰.针刺对高血压病胰岛素抵抗的影响[J].中国针灸,2003,23(3):165-167
[89]吴清明,冯国湘,汤雪飞.针刺开“四关”加百会穴温针灸对原发性高血压病人血浆中ET和NO的影响[J].中国针灸,2004,24(1):53-55
[90]邢孝民,黄志华,房玉珍.平肝潜阳针法对原发性高血压病人甲襞微循环的影响[J].中国临床康复,2005,9(7):106-107
[91]彭丽辉,冯玲媚,陈筑芳,等.艾灸对高血压病患者血压及NO、ET、SOD、MDA的影响[J].中国针灸,2004,24(3):157-159
[92]王宁,张昆,郑君.隔芪香散灸脐法治疗高血压肝阳上亢证30例.四川中医,2007,25(4):60-61
[93]张昆,郑君,王宁.隔药灸脐法治疗高血压肝阳上亢证30例.浙江中医杂志,2007,42f7):417-419
[94]陈华德,方针,王翀敏.耳尖放血治疗高血压病肝阳上亢证疗效观察[J].中国针灸,2004,24(4):229-231
[95]陈华德.耳尖放血疗法改善高血压病肝阳上亢证.中国社区医师,2006,22(312):30
[96]汤日鹏,宋顺福,周克义,等.耳尖放血疗法治疗高血压病肝阳上亢证临床观察.中医药学刊,2006,24(12):2219
[97]黄淑芳,梁纪文.高血压病的中医综合治疗.中国临床医生,2006,34(10):15-16
[98]匡海茜.耳穴贴压治疗原发性高血压100例[J].潍坊医学院学报,2004,26(5):94
[99]商翠莲.吴茱萸敷神阙穴治疗高血压60例[J].中医外治杂志,2003,12(2):46
[100]黄小平.五子散外敷涌泉穴对高血压昼夜杰律影响临床观察[J].按摩与导引,2004,20(3):25-27